

The story from Dr Mikael Stenborg, Copenhagen, Denmark.

In the fall of 2005 I was contacted by a patient who said that she was cured without operation from Breast Cancer by a drug called Ukrain. I had never heard about the drug before, so I was amazed when I found more than a hundred references on the medical database Medline, including many randomized clinical investigations with results previously unheard about. Later, in the fall of year 2006, my father, who by then was 89 years old started to have a very serious anemia, that required more and more blood transfusions.

He got the diagnose "myelodysplastic syndrome" from the hematological experts at the Danderyd University Hospital in Stockholm, Sweden

The **myelodysplastic syndromes** (MDS, formerly known as "preleukemia") are a diverse collection of [hematological](#) conditions united by ineffective production of blood cells and varying risks of transformation to [acute myelogenous leukemia](#) (AML). [Anemia](#) requiring chronic [blood transfusion](#) is frequently present. It usually have a progressive course, with more and more blood transfusions. Approximately one-third of patients with MDS progress to AML within months to a few years. The doctors at the Danderyd University hospitals had no curative treatment to present to my father, except for symptom treatment with blood transfusions.

I contacted Nowicky pharma, the manufacturer of Ukrain, and asked if they had any experience of using Ukrain against myelodysplastic syndrome. The answer was no, but they were interested in finding out if Ukrain was effective, so they provided me with some Ukrain for test purposes.

Before treatment with Ukrain, my fathers Hemoglobin was falling from 100 g/l to below 80 g/l in less then one month requiring at least one transfusion per month with a more and more frequent transfusion pattern.

After receiving a dose of 10 mg Ukrain twice weekly for a couple of months, my fathers blood values started to become normalized, and after one year of therapy, he very rarely needed transfusions. We paused with Ukrain for a couple of months without any recurrence of blood transfusion needs.

After the pause, his blood values where still OK, but his general condition had deteriorated. We gave him Ukrain again, with a positive result on mood and general well being.

I am very grateful to Dr Wassil Nowicky for helping my father, and as well as many other cancer patients all over the world and have decided that it is my duty as a doctor and human being to help spreading the information on this extremely interesting and promising drug to humanity. One of my actions in this direction was to nominate Dr Nowicky for the alternative Nobel Prize, the "Right Livelihood Award" in year 2007.

Copenhagen 4/6 2008

Mikael Stenborg MD

Kildegårdsvej 12 A

2900 Hellerup

Denmark

e-mail: jmstenborg@gmail.com